摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[(cyclopropylmethyl)oxy]-3-(methyloxy)benzene

中文名称
——
中文别名
——
英文名称
1-[(cyclopropylmethyl)oxy]-3-(methyloxy)benzene
英文别名
1-(Cyclopropylmethoxy)-3-methoxybenzene
1-[(cyclopropylmethyl)oxy]-3-(methyloxy)benzene化学式
CAS
——
化学式
C11H14O2
mdl
——
分子量
178.231
InChiKey
QDUFFJFZNJYLIV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    13
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    18.5
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为产物:
    参考文献:
    名称:
    Novel Synthesis of Desymmetrized Resorcinol Derivatives:  Aryl Fluoride Displacement on Deactivated Substrates
    摘要:
    A short, high-yielding synthesis of differentially substituted resorcinol derivatives has been developed that utilizes 1,3difluorobenzene as the starting material and employs sequential nucleophilic aromatic substitution (SNAr) reactions to generate desymmetrized products. The scope and limitations of the second SNAr reaction on the deactivated 1-alkoxy-3-fluorobenzene intermediates have been investigated. This methodology has also been employed in the synthesis of desymmetrized catechol derivatives from 1,2difluorobenzene.
    DOI:
    10.1021/jo0523868
点击查看最新优质反应信息

文献信息

  • Bicyclic Pyrrole Derivatives
    申请人:Nakahira Hiroyuki
    公开号:US20080318922A1
    公开(公告)日:2008-12-25
    Compounds represented by the general formula (I), prodrugs thereof, or pharmaceutically acceptable salts of both are provided as compounds which have high DPP-IV inhibiting activity and are improved in safety, toxicity and so on: (I) wherein the solid line and dotted line between A 1 and A 2 represents a double bond (A 1 =A 2 ) or the like; A 1 is C(R 4 ) or the like; A 2 is nitrogen atom or the like; R 1 is hydrogen atom, optionally substituted alkyl group, or the like; R 2 is hydrogen atom, optionally substituted alkyl group, or the like; R 3 is hydrogen atom, halogen atom, or the like; R 4 is hydrogen atom, hydroxyl, halogen atom, or the like; and Y is a group represented by the general formula (A) or the like; (A) [wherein m1 is 0, 1, 2 or 3; and the group (A) may be freed from R 6 or substituted with one or two R 6 's which are each independently halogen atom or the like.]
    提供了一种通式(I)、其前药或两者的药物可接受盐作为具有高DPP-IV抑制活性并在安全性、毒性等方面得到改进的化合物:(I)其中A1和A2之间的实线和虚线表示双键(A1=A2)或类似物;A1是C(R4)或类似物;A2是氮原子或类似物;R1是氢原子、可选取代烷基或类似物;R2是氢原子、可选取代烷基或类似物;R3是氢原子、卤原子或类似物;R4是氢原子、羟基、卤原子或类似物;Y是由通式(A)或类似物表示的基团;(A)[其中m1为0、1、2或3;基团(A)可以从R6中释放或用一个或两个R6替代,它们各自独立地是卤原子或类似物。]
  • BICYCLIC PYRROLE DERIVATIVES
    申请人:Nakahira Hiroyuki
    公开号:US20090192129A1
    公开(公告)日:2009-07-30
    Compounds represented by the general formula (I), prodrugs thereof, or pharmaceutically acceptable salts of both are provided as compounds which have high DPP-IV inhibiting activity and are improved in safety, toxicity and so on: (I) wherein the solid line and dotted line between A 1 and A 2 represents a double bond (A 1 =A 2 ) or the like; A 1 is C(R 4 ) or the like; A 2 is nitrogen atom or the like; R 1 is hydrogen atom, optionally substituted alkly group, or the like; R 2 is hydrogen atom, optionally substituted alkyl group, or the like; R 3 is hydrogen atom, halogen atom, or the like; R 4 is hydrogen atom, hydroxyl, halogen atom, or the like; and Y is a group represented by the general formula (A) or the like; (A) [wherein m1 is 0, 1, 2 or 3; and the group (A) may be freed from R 6 or substituted with one or two R 6 's which are each independently halogen atom or the like.]
    提供了由通式(I)表示的化合物,其前药或两者的药物可接受的盐,这些化合物具有高DPP-IV抑制活性,并在安全性,毒性等方面得到改善:(I),其中A1和A2之间的实线和虚线表示双键(A1 = A2)或类似物; A1是C(R4)或类似物; A2是氮原子或类似物; R1是氢原子,可选地取代的烷基或类似物; R2是氢原子,可选地取代的烷基或类似物; R3是氢原子,卤原子或类似物; R4是氢原子,羟基,卤原子或类似物; Y是由通式(A)或类似物表示的基团;(A)[其中m1为0,1,2或3;基团(A)可以从R6中释放或用一个或两个R6(它们各自独立地是卤原子或类似物)取代]。
查看更多

同类化合物

(R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (+)-6,6'-{[(1R,3R)-1,3-二甲基-1,3基]双(氧)}双[4,8-双(叔丁基)-2,10-二甲氧基-丙二醇 麦角甾烷-6-酮,2,3,22,23-四羟基-,(2a,3a,5a,22S,23S)- 鲁前列醇 顺式6-(对甲氧基苯基)-5-己烯酸 顺式-铂戊脒碘化物 顺式-四氢-2-苯氧基-N,N,N-三甲基-2H-吡喃-3-铵碘化物 顺式-4-甲氧基苯基1-丙烯基醚 顺式-2,4,5-三甲氧基-1-丙烯基苯 顺式-1,3-二甲基-4-苯基-2-氮杂环丁酮 非那西丁杂质7 非那西丁杂质3 非那西丁杂质22 非那西丁杂质18 非那卡因 非布司他杂质37 非布司他杂质30 非布丙醇 雷诺嗪 阿达洛尔 阿达洛尔 阿莫噁酮 阿莫兰特 阿维西利 阿索卡诺 阿米维林 阿立酮 阿曲汀中间体3 阿普洛尔 阿普斯特杂质67 阿普斯特中间体 阿普斯特中间体 阿托西汀EP杂质A 阿托莫西汀杂质24 阿托莫西汀杂质10 阿托莫西汀EP杂质C 阿尼扎芬 阿利克仑中间体3 间苯胺氢氟乙酰氯 间苯二酚二缩水甘油醚 间苯二酚二异丙醇醚 间苯二酚二(2-羟乙基)醚 间苄氧基苯乙醇 间甲苯氧基乙酸肼 间甲苯氧基乙腈 间甲苯异氰酸酯